Last updated 2 years ago
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA
20 patients around the world
Available in Argentina, Mexico
Studies have shown that stem cell treatment is safe and efficacious for the treatment of
Rheumatoid Arthritis (RA). Patients with RA will receive a single intravenous infusion of
cultured allogeneic adult umbilical cord derived mesenchymal stem cells. The total dose will
be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6,
12, 24, 36, and 48 months post treatment for safety and efficacy.
For patients with more severe disease requiring chemotherapeutic drugs such as methotrexate,
an autologous T Cell vaccine will be utilized created from the patient's own T cells obtained
by apheresis
The Foundation for Orthopaedics and Regenerative Medicine
1Research sites
20Patients around the world
Requirements for the patient
All Gender
Medical requirements
- Diagnosis of Rheumatoid ArthritisUnderstanding and willingness to sign a written informed consent document
- Active infectionActive cancerChronic multisystem organ failurePregnancyClinically significant Abnormalities on pre-treatment laboratory evaluationMedical condition that would (based on the opinion of the investigator) compromise patient's safety.Continued drug abusePre-menopausal women not using contraceptionPrevious organ transplantHypersensitivity to sulfur
Sites
Medyca Bosques
Recruiting
SponsorThe Foundation for Orthopaedics and Regenerative Medicine
Study typeInterventional
Requirements
All Gender
Unique study IDclinicaltrials.gov
NCT05003934
